

Resource Summary Report

Generated by PRECISE-TBI on Sep 5, 2026

Brilliant Violet 711(TM) anti-mouse/human CD44

RRID:AB_2564214

Type: Antibody

Proper Citation

BioLegend Cat# 103057, RRID:AB_2564214

Antibody Information

URL: http://antibodyregistry.org/AB_2564214

Proper Citation: BioLegend Cat# 103057, RRID:AB_2564214

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_2564214

Vendor: BioLegend

Catalog Number: 103057

Record Creation Time: 20231110T035210+0000

Record Last Update: 20260829T195455+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 711(TM) anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Grassmann S, et al. (2026) Stepwise epigenetic signal integration drives adaptive programming of cytotoxic lymphocytes. *Immunity*, 59(2), 339.

Xie X, et al. (2026) Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. *Cell reports*, 45(1), 116838.

Shamskhov EA, et al. (2026) Monocytic niches escape T cell surveillance and promote Mycobacterium tuberculosis persistence in lymph nodes. *Immunity*.

Gracia G, et al. (2026) Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy. *Cancer immunology research*, 14(3), 450.

Crotts SB, et al. (2026) ST8Sia6-dependent glycosylation restrains gut inflammation and pathogenic Th1 and Th17 programs. *Cell reports*, 45(5), 117347.

Zhang W, et al. (2026) A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. *Cell reports. Medicine*, 102932.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. *Immunity*, 58(7), 1742.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Cheung JF, et al. (2025) Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas. *Cancer cell*, 43(12), 2311.

Cortez VS, et al. (2025) IL-25-induced memory ILC2s mediate long-term small intestinal adaptation. *bioRxiv : the preprint server for biology*.

Nyberg WA, et al. (2025) In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313. *Immunity*, 58(2), 499.

Kastner AL, et al. (2025) Durable lymphocyte subset elimination upon a single dose of AAV-delivered depletion antibody dissects immune control of chronic viral infection. *Immunity*, 58(2), 481.

Cortez VS, et al. (2025) IL-25-induced memory type 2 innate lymphoid cells enforce mucosal immunity. *Cell*.

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. *Cell reports*, 44(7), 115933.

Cohen JA, et al. (2025) KMT2D coordinates antiviral CD4+ T cell responses through opposing effects on T follicular helper and cytotoxic gene expression. *Cell reports*, 44(6), 115775.

Conter L, et al. (2025) BLIMP1 controls GC B cell expansion and exit through regulating cell cycle progression and key transcription factors BCL6 and IRF4. *Cell reports*, 44(7), 115977.

Gbedande K, et al. (2024) Heightened innate immune state induced by viral vector leads to enhanced response to challenge and prolongs malaria vaccine protection. *iScience*, 27(12), 111468.

Li X, et al. (2024) Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation. *Immunity*, 57(7), 1603.

Graham JB, et al. (2024) Unique immune profiles in collaborative cross mice linked to survival and viral clearance upon infection. *iScience*, 27(3), 109103.

Ross RB, et al. (2024) PPAR γ Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1916.